Krystal Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Krystal Biotech (KRYS).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$320Upside to Avg. PT-0.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 15, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$361
Sep 24, 2026	Goldman Sachs	Andrea Newkirk	Reinstates	Buy	$441
Sep 21, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$392→$400
Aug 14, 2026	RBC Capital	Lisa Walter	Initiate	Outperform	$400
Aug 4, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$378→$386
Jul 14, 2026	B of A Securities	Alec Stranahan	PT Raise	Buy	$364→$396
Jun 18, 2026	TD Cowen	Ritu Baral	PT Raise	Buy	$306→$403
Jun 16, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$310→$361
Jun 1, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$310
May 22, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$310
May 18, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$310
May 5, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$371→$378
May 5, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$295→$300
May 4, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$310
Mar 27, 2026	Wolfe Research	Kalpit Patel	Initiate	Peer Perform	—
Feb 25, 2026	Guggenheim	Debjit Chattopadhyay	PT Raise	Buy	$224→$284
Feb 18, 2026	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$336→$371
Feb 18, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$220→$323
Feb 17, 2026	Jefferies	Roger Song	PT Raise	Buy	$310→$371
Feb 2, 2026	Goldman Sachs	Andrea Tan	PT Raise	Buy	$206→$327

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $361 price target.

Benzinga Newsdesk

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

Krystal Biotech reports clinical updates for KB113, showing over an 80% reduction in basal cell carcinoma lesions in Gorlin syndrome.

Vandana Singh

PRO
Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

Goldman Sachs analyst Andrea Newkirk reinstates Krystal Biotech (NASDAQ:KRYS) with a Buy and announces $441 price target.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $392 to $400.

Benzinga Newsdesk

PRO
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

RBC Capital analyst Lisa Walter initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Outperform rating and announces Price Target of $400.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the price target from $378 to $386.

Benzinga Newsdesk

Krystal Biotech Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Krystal Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

PRO
Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

PRO
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

PRO
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

PRO
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

People Also Watch

People Also Watch

Krystal Biotech Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Krystal Biotech Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target

Krystal Biotech Reports Over 80% Lesion Reduction in Rare Skin Cancer Trial

PROGoldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

PROB of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

PRORBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

PROCitigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $361 Price Target

PRO
Goldman Sachs Reinstates Buy on Krystal Biotech, Announces $441 Price Target

PRO
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $400

PRO
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400

PRO
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $386